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Abstract
Fibroblast growth factors and their receptors play a key role in cell proliferation, migration and differentiation.
Fibroblast growth factor receptor 2 (FGFR2) is involved in carcinogenesis and its altered expression has been
shown in several tumors, such as breast, thyroid and pancreatic cancer. The two isoforms of FGFR2 gene, FGFR2-
IIIb (also known as KGFR) and FGFR2-IIIc have been shown to exert differential roles in pancreatic cancer. FGFR2-
IIIc supports pancreatic cell proliferation, while overexpression of FGFR2-IIIb is correlated to major invasion and
metastasis formation. This review focuses on the role of FGFR2 signaling in pancreatic adenocarcinoma and the
potential use of FGFR2 tissutal expression as a predictive and/or prognostic marker. Moreover, it will discuss about
the potential use of strategies for FGFR2 signaling inhibition in the treatment of pancreatic cancer.
Keywords: Pancreatic adenocarcinoma; FGFR2; FGFR2-iiib;
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Introduction
FGFRs are a family of tyrosine kinase receptors consisting of four
members (FGFR1-4). These receptors are characterized by two or three
immunoglobulin-like extracellular domains, an intracellular tyrosine
kinase domain, and a carboxyl-terminus domain [1]. They are involved
in regulating cell proliferation, migration and differentiation during
vertebrate development, as well as in response to injury and tissue
repair [2]. In this review, we focus our attention on the FGFR2 gene,
which is subjected to an alternative splicing that generates two
isoforms, FGFR2-IIIb, predominantly expressed on epithelial cells, and
FGFR2-IIIc, detected in mesenchymal cells. FGFR2-IIIb has a role in
the control of epithelial growth and differentiation, while FGFR2-IIIc
receptor is involved in the proliferation of mesenchymal cells. The two
isoforms show a different affinity for ligands; in particular, FGFR2-IIIb
isoform binds with high affinity to KGF (also known as FGF7), FGF10
and FGF22, and with low affinity to FGF1 and FGF3, while the
FGFR2-IIIc isoform binds to FGF1, FGF2, FGF4, FGF5, FGF6, FGF8,
FGF9, FGF16, FGF17, FGF18, FGF20, FGF21 and FGF23 [3].
Some studies proposed that a shift between splicing isoforms may
be involved in tumor progression. For example, a switch between
FGFR2-IIIb and FGFR2-IIIc isoform in rat prostate and bladder cancer
models might contribute to alter the balance between epithelial and
mesenchymal cells and to promote epithelial-mesenchymal transition
[4,5]. However, FGFR2-IIIb isoform re-expression in prostate and
bladder cancer cell lines resulted in growth suppression in vitro and in
decreased tumor formation in vivo [6-8].
Up- or down-modulation of one or both FGFR2 isoforms has been
shown in several types of cancer, for example in thyroid, breast, lung,
stomach and pancreas cancer [9-12]. Genetic mutations of FGFR2
have been also observed, and they are correlated with cancer
susceptibility or poor prognosis. In breast cancer, single nucleotide
polymorphisms (SNPs) located within intron 2 of FGFR2 gene have
been associated to increased risk of cancer [13,14]. Missense mutations
of FGFR2 have been observed in breast, gastric and lung cancer. Some
of these mutations can alter ligand-receptor specificity or determine a
ligand-independent FGFR2 activation [15]. In the present work, we
discuss the role of FGFR2 signaling pathway in pancreatic cancer and
the potential use of FGFR2 inhibitors as anti-cancer therapies.
Role of FGFR2 in Pancreatic Adenocarcinoma
Pancreatic ductal adenocarcinoma (PDAC) is an aggressive human
malignancy with high mortalities among all malignancies [16]. Several
growth factors and their receptors are overexpressed in PDAC, such as
transforming growth factor-a, epidermal growth factor receptor, FGFs,
and FGFRs [17]. Several FGFs are overexpressed in pancreatic cancer
[18] and their altered expression has been linked to increased
pancreatic cancer cell motility, proliferation, invasion and metastatic
potential [19,20]. Expression levels of FGFR1 and FGFR2 have been
reported to be involved in pancreatic cancer development. FGFR1
overexpression is implicated in growth of pancreatic cancer cells
[21,22], while increase of FGFR2 phosphorylation is linked with
enhanced pancreatic cell proliferation, invasion and tumor
angiogenesis [23].
Differential expression of FGFR2-IIIb and its ligand has been shown
in different pancreatic cell types, such as acinar, ductal and islet cells
[24]. We also confirmed these results by immunohistochemical
staining on a tissue array of 40 cases of ductal adenocarcinoma, grade
1-3, with a home-made monoclonal antibody against FGFR2-IIIb [25].
Furthermore, several studies show concomitant overexpression of
FGFR2-IIIb and its ligand KGF in PDAC [26,27], which is correlated
with high expression of vascular endothelial growth factor-A (VEGF-
A), venous invasion, and poor prognosis [28]. In metastatic pancreatic
cancer cell lines, the upregulation of KGF secretion is linked with
pancreatic progression and metastatic formation, suggesting that the
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altered expression of KGF and FGFR2-IIIb may be involved in early
signals in the progression of pancreatic cancer [29].
As previously reported, normal pancreatic cells lack FGFR2-IIIc,
while enhanced expression of the latter has been detected in pancreatic
cancer cell lines and PDAC tissues, boosting proliferative ability in vivo
[30].
Several studies have shown a correlation between FGFR2 gene
amplification or single nucleotide polymorphism in intron 2 with
cancer progression [11,12,31]. FGFR2 amplification has been
associated to poorly differentiate gastric cancer [32]. Notably, an
amplification of FGFR2 was also detected in pancreatic cancer based
on cell line and xenograft aberration profiles originated from genome-
wide analysis [33]. Most importantly, FGFR2 inhibition by means of
specific shRNA, leads to cell proliferation, migration and invasion [34].
Soluble factors released from tumor stroma have been shown to play
a role in tumor growth. For example, cell-derived factor-1 (SDF-1/
CXCL12) released by fibroblasts can promote cancer cells proliferation,
while CXCR4 is released in several types of malignancies, such as
breast cancer [35] and pancreatic cancer [36,37]. Also FGF10,
produced by fibroblasts, has been demonstrated to induce cell
migration and invasion in pancreatic cancer cells [19], while FGF7 is
able to promote pancreatic cell proliferation. Nomura et al., have
investigated the role of FGF10/FGFR2 pathway in pancreatic cancer.
Their results demonstrated that FGF10 induces cell migration and
invasion, thus influencing the expression of genes related to cell
mobility, such as membrane type 1-matrix metalloproteinase (MT1-
MMP) and transforming growth factor beta (TGF- β1). In particular,
mRNA expression of MT1-MMP and TGF- β1 were upregulated by
FGF10 in CFPAC-1 cells.
FGF/FGFR Signaling as a Therapeutic Target
Pancreatic adenocarcinoma is characterized by high mortality,
incidence of metastatic disease and rapid progression. It is very
difficult to obtain an early diagnosis, and in the majority of cases at the
time of diagnosis patients just show several metastases, with an
unfavorable prognosis. Therefore, new therapies for pancreatic cancer
are extremely necessary. To detect new molecular mechanisms at the
basis of the onset and progression of this cancer might improve its
diagnosis and therapy.
Growth factors and their receptors have a role in several events that
occur in tumorigenesis [38]. Since FGFR, in particular, is involved in
cancer progression and invasion, its signaling may represent a
therapeutic target for anticancer therapy. Several therapeutical
approaches against FGFR are now available. Small molecular tyrosine
kinase inhibitors with anti-angiogenic activity against VEGFR and
PDGFR are currently in preclinical or clinical trial. Dovitinib
(TKI-258), an inhibitor of FGFR1, FGFR2 and FGFR3, showed
antitumor activity in FGFR-amplified breast cancer [39]. This inhibitor
has been also evaluated in bladder cancer and relapsed multiple
myeloma cases. An alternative therapeutical strategy is based on the
use of neutralizing antibodies. This method promises a high specificity
against the molecule of interest, thus allowing the development of
targeted therapies. Some of these monoclonal antibodies, just approved
by FDA, are nowadays used as anticancer monotherapy or in
combination with standard chemotherapy. For example, anti-EGFR
antibodies, such as Cetiximab and Panitumumab, are now used in the
treatment of colon cancer, while the anti-HER2 antibody Trastuzumab
is currently administered to breast cancer and gastric cancer patients
in combination with chemotherapy. Also FGFs and FGFRs became a
relevant target for the development of specific neutralizing antibodies.
Specific antibodies against FGFR1/FGFR3 were tested in bladder and
myeloma cancer with successful results [40,41]. Another approach
consists in the use of FGF ligand traps that prevent FGF binding with
its receptor.
FGFR2 has a key role in the establishment of cancer, so it represents
a potential target for cancer treatment. Monoclonal antibodies for this
receptor have been produced. Bai et al., created a specific antibody
against FGFR2-IIIb isoform that is able to suppress ligand induced
phosphorylation [42]. As concerning pancreatic cancer therapy, the
use of monoclonal antibodies against growth factors has been
evaluated. Phase I clinical trials showed the feasibility of
Panitumumab, a monoclonal antibody against epidermal growth factor
(EGFR), for the treatment of patients with locally advanced pancreatic
cancer (LAPC). The combined use of panitumumab, at a maximum
tolerated dose of 1.5 mg/kg, with gemcitabine-based
chemoradiotherapy, can be safely and effectively used in LAPC
patients [43]. In PDAC, not only cancer cells but also tumor
microenvironment contributes to the initiation, progression, and
metastasis of tumor. Therefore, pancreatic cancer is extremely
complex, and the use of single monoclonal antibody therapy is not a
successful therapeutic strategy. Nevertheless, the discovery of new
predictive and response biomarkers is necessary to develop new
therapeutic approaches. In light of these considerations, FGFR2 might
be a marker for pancreatic cancer and its investigation is needed to
evaluate its potential use as a target for therapy.
Limitations of anti-FGFR2 Therapeutic Approaches
FGFR2 plays a relevant role in pancreatic cancer and it might
represent a potential marker for new therapeutic strategies. In
particular, in this review we focused our attention on FGFR2-IIIb/KGF
signaling, which is involved in pancreatic cancer progression, invasion
and metastasis formation. A therapeutic approach against FGFR2-IIIb
isoform could be useful, but the lack of highly specific drug against
FGFR2-IIIb is the major limitation of this approach. In fact, the use of
pan-FGFR inhibitors might influence also other signaling. Nowadays,
clinical trials on tyrosine kinase inhibitors direct against FGFR1/2/3
are available, but these inhibitors do not target all activating mutation.
Therefore, studies to determine which aberration plays a role in
tumorigenesis are required in order to understand the implication of
genomic alteration.
GP369 is the only antibody used in vitro and in vivo to suppress IIIb
isoform in amplified human breast and gastric cancer [42]. This
antibody is efficient only in cancers with FGFR2 amplification, so it
would be necessary to evaluate FGFR2-IIIb expression and type of
mutation before administration of FGFR2-IIIb inhibitor to pancreatic
cancer patients. Therefore, FGFR2 evaluation should be introduced in
routine diagnosis. For this reason, the use of therapeutic approach base
on FGFR2 might have several limitations due to the need for expensive
genetic analyses.
Conclusions
Pancreatic adenocarcinoma is characterized by high mortality and
poor prognosis due late diagnosis. The lack of predictive and
prognostic markers supports the aggressive nature of pancreatic
tumors. Several growth factors and their receptors have been shown to
be involved in cancer onset and progression, and the investigation of
Citation: Vescarelli E, Ceccarelli S, Angeloni A (2015) Role of Fibroblast Growth Factor Receptor 2 in Pancreatic Cancer: Potential Target for
New Therapeutic Approach?. Pancreat Disord Ther 5: 164. doi:10.4172/2165-7092.1000164
Page 2 of 4
Pancreat Disord Ther
ISSN:2165-7092 PDT, an open access journal Volume 5 • Issue 3 • 1000164
their potential as predictive and prognostic markers might be useful to
ameliorate cancer diagnosis.
FGFRs family has an important role during physiological and
pathological processes, and also in carcinogenesis. FGFR2 altered
expression was observed in different types of cancer, including
pancreatic ductal adenocarcinoma. The overexpression of this receptor
is associated to major invasion, cell proliferation and metastasis
formation; therefore FGFR2 up regulation might be considered an
early step in the development of pancreatic cancer. For this reason,
FGFR2 might represent a potential marker for diagnostic and
prognostic evaluation of pancreatic cancer.
The identification of novel molecules involved in pancreatic tumor
progression might result in the development of promising therapeutic
strategies, thus increasing the available anticancer agents and
treatment opportunities. Nowadays, different therapeutic approaches
have been produced against FGFR2, and the current information about
the relationship between this receptor and pancreatic cancer clearly
indicate that the inhibition of this signalling pathway could find an
application also in the treatment of PDAC.
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